This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Background Hypertrophic cardiomyopathy (HCM) is commonly associated with atrialfibrillation (AF), but its impact on outcomes in real-world practice is uncertain. years) were enrolled in the EURObservational Research Programme (EORP) Cardiomyopathy/Myocarditis Registry. Methods Overall, 1739 adult patients with HCM (40.9%
BackgroundNon-valvular atrialfibrillation (NVAF) significantly increases ischemic stroke and systemic embolism (SE) risks. Despite the proven efficacy of oral anticoagulants (OAC) in reducing these risks, their underutilization highlights a gap in clinical practice. Early OAC initiation (74.9%
The increasing prevalence of atrialfibrillation (AF) in adults with congenital heart disease raises significant questions regarding its management. Finally, any remaining gaps in knowledge and potential areas of future research are highlighted. Journal of the American Heart Association, Ahead of Print.
Additional relevant studies, published through November 2022, during the guideline writing process, were also considered by the writing committee and added to the evidence tables, where appropriate.StructureAtrial fibrillation is the most sustained common arrhythmia, and its incidence and prevalence are increasing in the United States and globally.
16, 2025 Primary results from the DEFINE AFib clinical study show the Medtronic LINQ family of insertable cardiac monitors (ICM), paired with a novel algorithm, were able to detect atrialfibrillation episodes and properly risk stratify patients as high risk prior to an AF-related healthcare utilization 80% of the time.
To investigate standardized incidence of atrialfibrillation (AF) in individuals with type 1 diabetes (T1DMM) compared with matched controls from the general population. Additionally, to examine optimal levels.
Research Highlights: A clinical trial with adults who have atrialfibrillation (AFib) and an implanted heart device found similar improvements to the amount of time they experienced arrhythmia regardless of whether they received standard care.
This study aimed to identify the riskfactors for postoperative atrialfibrillation in patients with valvular atrialfibrillation, and establish predictive models of atrialfibrillation recurrence.
Background Postoperative atrialfibrillation (POAF) is a frequent complication that may increase morbidity and mortality risk following cardiac surgery. Recent studies have reported associations between elevated SII and increased POAF risk; however, significant heterogeneity exists regarding its predictive efficacy.
Atrialfibrillation (AF) is the most common heart rhythm disorder in clinical practice. It worsens the quality of life of patients, leads to an increase in the mortality rate because of its association with a high risk of thromboembolic complications. However, most research in this area has focused on hospital patients.
Titled "Real-world Data Affirms Safety and Effectiveness of Low/Zero Fluoroscopy AtrialFibrillation Ablation," the study was presented as a late-breaker at the 29th Annual International AF Symposium. Real-world Data Affirms Safety and Effectiveness of Low/Zero Fluoroscopy AtrialFibrillation Ablation [abstract].
A projected rise in heart disease and stroke – along with several key riskfactors, including high blood pressure and obesity – is likely to triple related costs to $1.8 Smith Center for Outcomes Research in Cardiology and director of the cardiac critical care unit at Beth Israel Deaconess Medical Center in Boston, Mass.
Atrialfibrillation (AF) is the most prevalent arrhythmia in clinical practice, and obesity serves as a significant riskfactor for its development. The underlying mechanisms of obesity-related AF remain intri.
Owing to improved management, the life expectancy of patients with hemophilia has increased significantly and predisposes them to risk of cardiovascular diseases and thrombotic events. The primary outcome was to estimate the prevalence of cardiovascular riskfactors in patients with hemophilia compared to the general population.
Atrialfibrillation (AF), the most common arrhythmia, has been closely linked to sepsis in prior research. BackgroundSepsis is characterized by high morbidity and mortality rates, alongside limited therapeutic efficacy. However, the specific mechanisms through which sepsis leads to new-onset AF remain poorly understood.
Treatment with the Type 2 diabetes medication metformin, lifestyle changes, or a combination of both did not improve atrialfibrillation (AFib) burden or progression when compared with standard care, according to preliminary late-breaking science presented Nov. 18 at the American Heart Association's Scientific Sessions 2024.
BackgroundObesity is an important riskfactor for atrialfibrillation (AF) development and progression. Furthermore, obesity reduces health-related quality of life (HRQoL), an essential indicator for treatment efficacy of AF ablation.
Introduction:Intracranial hemorrhage (ICH) is the most severe adverse effect of anticoagulation in atrialfibrillation (AF) patients. Hypertension, diabetes, hyperlipidemia, and chronic kidney disease are well-known cardiovascular riskfactors for ICH.
September is National AtrialFibrillation (AFib) Awareness Month, a time dedicated to raising awareness about one of the most common yet often misunderstood heart conditions. Understanding AtrialFibrillationAtrialFibrillation is characterized by an irregular and often rapid heart rhythm that can lead to poor blood flow.
Background and objective Patients with both coronary artery disease (CAD) and atrialfibrillation (AF) are at a high risk of major adverse cardiovascular and cerebrovascular events (MACCE) during hospitalization. Accurate prediction of MACCE can help identify high-risk patients and guide treatment decisions.
September is National AtrialFibrillation (AFib) Awareness Month, a time dedicated to raising awareness about one of the most common yet often misunderstood heart conditions. Understanding AtrialFibrillationAtrialFibrillation is characterized by an irregular and often rapid heart rhythm that can lead to poor blood flow.
Age is an independent riskfactor for the development of atrialfibrillation (AF). However, how natural aging predisposes to increased AF risk is currently unclear. Investigation prior to overt structural remodeling may therefore be required.
A Cedars-Sinai-led team developed an echocardiography AI model that accurately detects patients with atrialfibrillation – including asymptomatic patients – potentially revealing a new “opportunistic screening” method to drive earlier AFib detection and treatment.
Five highly-anticipated late-breaking clinical trial sessions, an ACC/AHA guidelines update session and a host of featured clinical research sessions have been announced by program planners for the American College of Cardiology’s 73 rd Annual Scientific Session & Expo to be held April 6-8 in Atlanta, GA. The Guidelines Sessions at ACC.24
Complications can occur during each phase, with long-term survivors facing increased risks for late effects such as cardiovascular disease, secondary malignancies, and endocrinopathies. In adults, arrhythmias such as atrialfibrillation and flutter are the most frequent acute cardiovascular complication.
The prevalence of HF riskfactors was high: hypertension, 61.9%; former or current smoking, 53.7%; obesity 34.8%; diabetes; 24.7%; and chronic kidney disease; 22%. Overt cardiovascular disease, which ranged from 2.1% (HF) to 13.6% (atrialfibrillation), was less common. were female, 25.6% were Black, 12.8% were White.
” — Dr. Matthew Walker This statement may seem a bit hyperbolic, but it accurately summarizes most of the available research on sleep and health. Sleep duration has traditionally received most of the attention as a modifiable riskfactor. . “The shorter your sleep, the shorter your life.” 1 Zheng, N.S.,
Different riskfactors affect the intensive care unit (ICU) stay after cardiac surgery. This study aimed to evaluate these riskfactors. A retrospective analysis was conducted on clinical, operative, and outcome data from 1070 patients (mean age: 59 ± 9.8&
We performed the Cox regression analysis to investigate the riskfactors for mortality. The very young group also had lower rates of CRF, previous MI and atrialfibrillation. We found that the ≤40-year-old group with MINOCA had 12% mortality rates during the follow-up. P = 0.02] in the ≤40-year-old group.
Research has increasingly shown that quality sleep plays a pivotal role in heart health. Chronic sleep deprivation can disrupt this natural rhythm, resulting in sustained high blood pressure, which strains the heart and increases the risk of heart disease.
While these findings provide preliminary insight, further research is crucial to corroborate our results and delineate their potentially transformative implications on patient care, particularly in the context of surgical interventions. The patient underwent both FDG‐PET/CT and NaF‐PET/CT imaging.
During its Annual Conference, HRS 2024, the Heart Rhythm Society (HRS) announced findings from three new studies demonstrating the safety and efficacy of pulsed field ablation (PFA), a nonthermal ablation treatment for patients with atrialfibrillation (AF). See full findings from the FARADISE, admIRE Study, and Advent Trial here.
When we explore the three traditional cardiometabolic riskfactors (obesity, type 2 diabetes, and dyslipidemia) and the emerging cardiometabolic riskfactor of non-alcoholic fatty liver disease, we unearth a complex interplay of societal, biological, genetic, and environmental factors.
2,3 Approximately 1 in 4 adults over the age of 40 are at risk for developing AFib. 6 Learn more about Biosense Webster's PFA research and clinical evidence here. Global epidemiology of atrialfibrillation: An increasing epidemic and public health challenge. Epidemiology of AtrialFibrillation in the 21st Century.
The PulseSelect PFA system, together with the CE Marked Affera mapping and ablation system and our strong Cryo platform, enables us to provide a broad portfolio of solutions to clinicians and their patients, all developed with years of research and supported by compelling scientific evidence." Roth GA, Mensah GA, Johnson CO et al.
AF Often Asymptomatic: Even for atrialfibrillation (AF)the most commonly symptomatic arrhythmiaover half of all cases were asymptomatic. If left untreated, certain arrhythmias can damage the heart, brain, or other organs 4 and increase the risk of stroke or death. 2016;11(8). doi:10.1371/journal.pone.0160181 1991;22(8):983-988.
Heart disease remains one of the leading causes of death worldwide, often attributed to a mix of lifestyle choices, environmental factors, and genetic predispositions. This blog explores how genetics influence heart health and whether mitigating these inherited risks is possible. Can You Prevent Heart Disease if Its in Your Genes?
Researchers hypothesized that an AI program trained to analyze echocardiograms might help clinicians detect early, subtle changes in the hearts of patients with undiagnosed arrhythmias. “We Atrialfibrillation can come and go, so it might not be present at a doctor’s appointment. An estimated 12.1
milla1cf Wed, 12/13/2023 - 10:24 December 13, 2023 — A new artificial intelligence (AI) model designed by Scripps Research scientists could help clinicians better screen patients for atrialfibrillation (or AFib)—an irregular, fast heartbeat that is associated with stroke and heart failure.
Background Chronic kidney disease (CKD) and atrialfibrillation (AF) are increasing in prevalence globally and share common riskfactors. Thus, further research is required as the lack of generalisation of findings is a rate-limiting factor for improved DOAC management in AF and CKD.
Background Heart failure (HF) is not included in atrialfibrillation (AF) bleeding risk prediction scores, reflecting uncertainty regarding its importance as a riskfactor for major haemorrhage. Results Over 7.56
The whole process can easily take 10-15 years and therefore patients may continue to be managed in sub-optimal manner for this duration of time even when there is available research to say that things could be done better. Today I wanted to talk about some troubling research in the field of AF. AF stands for atrialfibrillation.
Background:Migraine with aura (MA) is recognized as an independent riskfactor for acute ischemic stroke (AIS). However, the short-term risk of stroke, particularly within 90 days of hospitalization, has not been thoroughly evaluated on a national scale. Stroke, Volume 56, Issue Suppl_1 , Page ADP51-ADP51, February 1, 2025.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
88 
Let's personalize your content